Hotflash inc

Hotflash inc

Share this post

Hotflash inc
Hotflash inc
Fezo's a go (and it's Veozah now)

Fezo's a go (and it's Veozah now)

+ my favorite evidence-based supplement for hot flashes

Hotflash Inc's avatar
Hotflash Inc
May 13, 2023
∙ Paid
8

Share this post

Hotflash inc
Hotflash inc
Fezo's a go (and it's Veozah now)
2
Share
woman putting her hand on her lips
I have no idea if the pill will be shaped like that/Photo by danilo.alvesd on Unsplash

This is your free weekend version of Hotflash inc. Previously I’ve shared my analysis of fezolinetant with paid subscribers, but I think it’s important that everyone gets it now that it will be hitting shelves in the US. The free roundup of hopefully helpful things will resume next week.

The US Food and Drug Administration approved Astellas Pharma’s non-hormonal drug for hot flashes this week. This means a 45mg daily dose of Veozah – which contains fezolinetant, which is what we’ve been calling it until this sudden new name appeared Friday – is the first such medication to make it to market. The Japanese drugmaker, which has also applied for regulatory review in EU, Switzerland and Australia, says Veozah could be in US pharmacies within weeks.

Previously the only non-hormonal, FDA-approved treatment for hot flashes was the anti-depressant paroxetine. If you want to read the FDA’s report for yourself, …

Keep reading with a 7-day free trial

Subscribe to Hotflash inc to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Hotflash inc
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share